Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, US, March 09, 2022 (GLOBE NEWSWIRE) -- Facts and Factors has published a new research report titled “eSIM Market By Use (Laptops, Smartphones, M2M, Tablets, Connected Cars, and Wearables),...
-
BERKELEY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that...
-
Virginia Beach, March 08, 2022 (GLOBE NEWSWIRE) -- Virginia Beach, Virginia - Virginia Beach, VA based Proactive Healthcare Recruiters is looking for nurses who wish to take the next step of...
-
VANCOUVER, British Columbia, March 02, 2022 (GLOBE NEWSWIRE) -- Norsemont Mining Inc. (CSE: NOM, OTCQB: NRRSF, FWB: LXZ1) (“Norsemont” or the “Company”) is pleased to announce the second tranche of...
-
KORSUVA™ (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed Initiation of Oral KORSUVA (difelikefalin) Phase 3 pruritus...
-
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...
-
SANTA BARBARA, Calif. och STOCKHOLM, Sverige, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences (”Palette”), ett globalt företag inom medicinteknik som arbetar för att förbättra...
-
BILLERICA, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, today announced...
-
Partnership leverages Palette’s specialty sales team to increase promotional footprint of PYLARIFY within the urology call point SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Feb. 24, 2022 (GLOBE...
-
On track to present additional interim data from dose-escalation portion of the ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy on February 28, at 4:30 p.m....